PARP inhibitors and immunotherapy in ovarian cancer: From research to practice
27 Jan 2020
The age of genomic profiling
Prof Cengiz Yakicier - Acıbadem University, Istanbul, Turkey
27 Jan 2020
Identifying BRCA mutations for breast and ovarian cancer
Prof Alena Savanevich - Grodno State Medical University, Grodno, Belarus
27 Jan 2020
Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause i...
Prof Deborah Fenlon - Swansea University, Swansea, UK
12 Dec 2019
What should be the HPV vaccine strategy for India?
Dr Rengaswamy Sankaranarayanan - WHO-IARC, Lyon, France
7 Nov 2019
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
4 Oct 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
28 Sep 2019
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fall...
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
28 Sep 2019
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer ...
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
28 Sep 2019
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
28 Sep 2019
